According to #msg-17352091, approximately 10% of the worldwide HIV population has chronic HBV infection. The % is higher in Asia and lower in the West.
>anyone have an idea of the size of this market (i.e. coinfection meeting criteria for HBV therapy but not HIV therapy)?<
I think the way you phrased the question underestimates the market size because the addressable market is not limited to patients who can’t meet the criteria for standard HIV therapy. Rather, the addressable market also includes patients whose CD4 counts are stable and are advised by their docs to get treated for HBV first.
Market Data 
Markets 
AI
